Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Supplementary Materials of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3323)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Nov 19, 2024 (publication date) through Jul 25, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Psychiatry
ISSN
2220-3206
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Xu BY, Jin K, Wu HS, Liu XJ, Wang XJ, Sang H, Li KQ, Sun MJ, Meng HQ, Deng HL, Xun ZY, Yang XD, Zhang L, Li GJ, Zhang RL, Cai DF, Liu JH, Zhao GJ, Liu LF, Wang G, Zhao CL, Guo B, Jin SC, Huang LY, Yang FD, Zheng JM, Zhan GL, Fang MS, Meng XJ, Zhang GY, Li HM, Liu XL, Li JH, Wu B, Li HY, Chen JD. Who can benefit more from its twelve-week treatment: A prospective cohort study of blonanserin for patients with schizophrenia. World J Psychiatry 2024; 14(11): 1735-1745 [PMID: 39564169 DOI: 10.5498/wjp.v14.i11.1735] |
|---|---|
| URL: | https://www.wjgnet.com/2220-3206/full/v14/i11/1735.htm |
| Number | Citing Articles |
| 1 |
Jinhao He, Haitao Chen, Xuehu Luo, Cong Li, Mo Sun, Xiaoling Liu, Chenning Zhang. Post-marketing safety analysis of blonanserin: a retrospective pharmacovigilance study using the Japanese adverse drug event report database (2008–2024). European Journal of Pharmacology 2025; 1003: 177933 doi: 10.1016/j.ejphar.2025.177933
|